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Abstract
Malaria is caused by multiple different species of protozoan parasites, and interventions in
the pre-elimination phase can lead to drastic changes in the proportion of each species
causing malaria. In endemic areas, cross-reactivity may play an important role in the protec-
tion and blocking transmission. Thus, successful control of one species could lead to an
increase in other parasite species. A few studies have reported cross-reactivity producing
cross-immunity, but the extent of cross-reactive, particularly between closely related spe-
cies, is poorly understood. P. vivax and P. knowlesi are particularly closely related species
causing malaria infections in SE Asia, and whilst P. vivax cases are in decline, zoonotic P.
knowlesi infections are rising in some areas. In this study, the cross-species reactivity and
growth inhibition activity of P. vivax blood-stage antigen-specific antibodies against P. know-
lesi parasites were investigated. Bioinformatics analysis, immunofluorescence assay, west-
ern blotting, protein microarray, and growth inhibition assay were performed to investigate
the cross-reactivity. P. vivax blood-stage antigen-specific antibodies recognized the mole-
cules located on the surface or released from apical organelles of P. knowlesi merozoites.
Recombinant P. vivax and P. knowlesi proteins were also recognized by P. knowlesi- and P.
vivax-infected patient antibodies, respectively. Immunoglobulin G against P. vivax antigens
from both immune animals and human malaria patients inhibited the erythrocyte invasion by
P. knowlesi. This study demonstrates that there is extensive cross-reactivity between anti-
bodies against P. vivax to P. knowlesi in the blood stage, and these antibodies can potently
inhibit in vitro invasion, highlighting the potential cross-protective immunity in endemic
areas.
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Author summary
In recent years, malaria initiatives have increasingly shifted focus from achieving malaria
control to achieving malaria elimination. However, the interventions used are leading to
drastic changes in the proportions of different Plasmodium species causing clinical infec-
tion, particularly within Southeast Asia. Little is known about how these different parasite
species interact/compete in nature or whether exposure to one species could cause some
level of protection against another. We examined cross-reactive antibody responses to key
parasite proteins with roles in red blood cell invasion and identified novel cross-species
reactivity among the closest of malaria affecting the human population (P. vivax and P.
knowlesi). This comprehensive analysis provides evidence that cross-reactive immunity
could play an important role in areas where species distributions are perturbed by malaria
control measures, and future efforts to identify the specific cross-reactive epitopes
involved would be invaluable both to our understanding of malaria immunity and vaccine
development.
Introduction
Malaria remains a deadly scourge in humans, with over 200 million cases and close to a half-
million deaths reported annually [1]. Protozoan malaria parasites are transmitted by sporozo-
ite inoculation by a mosquito vector into the human [2]. Five Plasmodium species infect
humans; Plasmodium falciparum, P. vivax, P. ovale, P. malariae, and zoonotic malaria parasite
P. knowlesi [2,3]. P. falciparum is the most virulent species and leads to most severe cases in
Africa, while P. vivax is widely distributed and predominates in regions of Southeast Asia and
South America [1]. Recently, a monkey malaria parasite, P. knowlesi, has been found to be
cause a significant number of human infections in Southeast Asian countries [4–7].
In recent years, malaria initiatives have increasingly shifted focus from achieving malaria
control to achieving malaria elimination. Interventions are leading to drastic changes in the
proportions of different Plasmodium species affecting populations. For example, as P. vivax
forms latent hypnozoite stages, infection rates are often slower to decline under control mea-
sures that P. falciparum [8]. In most areas where malaria is endemic, two or more human para-
sites coexist [9], and mixed infections with three malaria parasite species (P. falciparum, P.
vivax, and P. knowlesi) have been identified in southern Myanmar, Thailand and Sabah,
Malaysia [10–12]. However, little is known about how the different parasite species interact/
compete in nature or whether exposure to one species could cause some level of protection
against another. If cross-species immunity is important, the successful control of one species
could lead to increases in the frequency or severity of infections from other Plasmodium spe-
cies [9,13]. Previous studies looking at patients concurrently infected with multiple Plasmo-
dium species demonstrated clear cross-regulatory patterns, including evidence for density-
dependent regulation of parasitaemia and peak parasitaemias for each parasite forming
sequential patterns [14]. Density-dependent regulation of parasitemia and specific immune
responses targeting particular antigens could explain the prevalence of coinfection patterns in
endemic areas [14].
An extreme example of how malaria control can affect species distribution is in Malaysia,
where successful control of human malaria has led to a significant decline in P. falciparum and
P. vivax cases at the same time as zoonotic P. knowlesi cases have dramatically increased. For
example, in Sabah, P. knowlesi caused less than 5% of malaria cases in 2004, but in 2017, it
was responsible for 98% of cases [15,16]. Equally, it is also possible that the removal of P.
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falciparum or P. vivax from populations could have an effect on the spread or pathogenicity of
other human parasites such as P. ovale and P. malariae which often cause subclinical infections
[17].
However, cross-species immunity in malaria has been largely ignored in the last few
decades [14]. Previous reports have observed cross-reactivity between P. falciparum and P.
malariae and between P. falciparum and P. vivax due to conserved/homologous plasmodial
proteins and the presence of shared B- and T-cells epitopes [18–25]. P. vivax antigens were rec-
ognized by sera from P. vivax and P. falciparum clinical patients [20,22]. Naturally acquired
antibodies in P. falciparum-infected patients inhibit the invasion of hepatocytes by rodent
malaria sporozoites [18]. Previous reports found that past exposure to P. vivax or P. malariae
leads to lower morbidity and mortality following P. falciparum exposure [14,26]. However, lit-
tle is known about which factors affect the cross-reactivity observed in those previous reports.
In addition, the identification of species-transcending inhibitory antibodies could provide a
powerful tool for vaccine development, particularly as these antibodies are far more likely to
result in strain-transcending effects, which has been a major challenge in malaria vaccine
research [27].
P. knowlesi and P. vivax are phylogenetically closely related [28], and approximately 89% of
P. vivax genes have orthologues in P. knowlesi [29]. In silico analysis has demonstrated that
there is a high degree of homology among plasmodial proteins, especially those of P. vivax, P.
knowlesi and P. cynomolgi [28]; thus, cross-reactivity may play an important role in the preva-
lence patterns observed in endemic areas of Southeast Asian countries where both human and
primate malaria coexist. It also remains interesting to explore the existence of cross-reacting
epitopes in blood-stage malaria vaccine candidates including P. knowlesi [30]. The disease
dynamic change has been seen in Malaysia while decreasing human Plasmodium species is
observed, the increasing of P. knowlesi infection is inevitable [15]. The possibility of waning
cross-protective P. vivax antibodies may contribute to increased zoonotic Plasmodium infec-
tion [31]. It is in line with our previous study that P. vivax antibodies inhibited the P. knowlesi
invasion in vitro [25].
This study presents a systematic analysis of cross-species reactivity of antibodies against P.
vivax blood-stage antigens and their inhibition activities against human erythrocyte invasion
by P. knowlesi. We also observed that antigen-specific IgG antibodies from P. vivax-infected
patients could inhibit erythrocyte invasion in P. knowlesi parasites. These data indicate that
significant cross-species reactive antibodies are generated during malaria infections and that
these may play a role in susceptibility or pathogenicity, particularly between closely related
species like P. vivax and P. knowlesi. It suggests that the potential for a developed vaccine
against multiple Plasmodium species should be examined in more detail.
Materials and methods
Ethics statement
Blood samples were taken from human subjects, age 18–70 years old after written-informed
consent was obtained from all subjects. All experimental protocols involving human samples
were approved by the Kangwon National University Hospital Ethical Committee (IRB No.
2014-08-008-002), the University of Malaya Medical Ethics Committee (Ref No. 817.18), and
the Medical Research Ethics Committee (MREC), Ministry of Health, Malaysia (National
Medical Research register ID No. 13079), in accordance with relevant guidelines and regula-
tions. Blood samples were collected from P. knowlesi-infected patients in EDTA-vacutainer
tubes provided by the University of Malaya Medical Center (UMMC), Malaysia during 2010–
2013, on the day when the patients were positively diagnosed with malaria. All P. knowlesi
PLOS NEGLECTED TROPICAL DISEASES Cross-species reactivity of Plasmodium knowlesi and P. vivax
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008323 June 19, 2020 3 / 21
samples used for this study were confirmed by species-specific PCR as described elsewhere [4].
The patients’ serum were collected from symptomatic patient visiting at endemic areas of
Malaysia with parasitemia 0.207% in average (ranging from 0.003 to 1.380%) and age 38 years
in average (range from 6 to 72). However, we did not obtain information about history of pre-
vious malaria infection from patients. P. vivax-infected patients were recruited from a P.
vivax-endemic area in Gangwon province, the Republic of Korea (ROK) where P. vivax is
major Plasmodium species, there is no P. knowlesi infection in this area [1]. Patients with P. fal-
ciparum infection were excluded in this study. The sera were collected from symptomatic
patient visiting at local health centers and clinics in Gangwon Province, ROK with parasitemia
ranging from 0.027 to 0.630%, mean 0.121%) and age 18 to 60 years (mean 28). P. vivax and P.
knowlesi eight patient serum samples were pooled after species-specific PCR and eight health
individuals without any Plasmodium infection. A total 70 individual P. vivax-, P. knowlesi-
infected patients serum and health individuals were used for individual immunoscreening
after preliminary pooled-serum screening. Patients without malaria were recruited from a
population of healthy individuals living in nonendemic areas of the ROK; malaria negativity
was confirmed by microscopy and PCR.
Sequence analysis of amino acid identity
The target antigens were selected from our previous studies that were localized in different api-
cal organelles/ merozoite surface of P. vivax and were recognized by human patients serum
(Table 1, see references). Amino acid sequences of P. vivax (Sal I and P01 strains) and P. know-
lesi (H strain) were retrieved from PlasmoDB (www.plasmodb.org) [32] and aligned. Clustal
W program was used to make a pairwise alignment to determine the percent amino acid iden-
tity (Table 1 and S1 Fig).
In vitro culture of blood-stage P. knowlesi parasites
The human-adapted P. knowlesi A1-H.1 strain was maintained with fresh human erythrocytes
in RPMI 1640-based medium (Invitrogen/Life Technologies, Grand Island, NY) as described
previously [53].
Recombinant protein expression
P. vivax recombinant proteins were generated by wheat germ cell-free or E. coli expression sys-
tems in our previous studies [25,42,44,50]. DNA fragments encoding PvRBP1a-34, Pv41, or
PvRhopH2 were amplified from a Korean vivax isolate with primers PvRBP1a-34_F (ggtcgcg
gatccgaattcATGAACGAACTAGGTATAGACATT) and PvRBP1a-34_R (ggtggtggtgctcgag
TTCAAACTCTATCTTCAGTTC); Pv41_F (ggtcgcggatccgaattcATGGAACACATCTGCGAT
TTTAC) and Pv41_R (ggtggtggtgctcgagCTCCTGGAAGGACTTGGCA); and PvRhopH2_F
(ggtcgcggatccgaattcATGGAGCTGAGCCACAGC) and PvRhopH2_R (ggtggtggtgctcgag
CTTCTCCACATCCTCGTGGT), respectively. Small letters indicate the plasmid-derived
sequence and underlined letters indicate enzyme restriction sites, EcoRI and XhoI, respec-
tively. High fidelity KOD-plus kit (Toyobo Co., Osaka, Japan) was used with an initial denatur-
ation step at 94˚C for 2 min, followed by 35 cycles of 94˚C for 15 sec, 60˚C for 30 sec, and
58˚C for 1.5 min and a final extension step at 68˚C for 10 min. The amplicons were purified
using a gel extraction kit and ligated into the pET28a(+) expression vector (Novagen, Madison,
WI) for PvRBP1a-34 or the pET23a(+) expression vector for Pv41 and PvRhopH2 with a His-
tag. Correctly ligated plasmids were transformed into E. coli BL21(DE3) pLysS (Life Technolo-
gies) for recombinant protein expression. Recombinant protein expression was induced with
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0.1 mM isopropyl-β-D-thiogalactopyranoside (IPTG; Sigma-Aldrich, St. Louis, MO). All
recombinant proteins were solubilized, purified, and refolded as described elsewhere [47,54].
Meanwhile, P. knowlesi recombinant proteins were expressed for this study using wheat
germ cell-free system for immunoscreening using specific primers (S2 Table), the procedures
were described elsewhere[47]. Recombinant PkDBPα protein expression was described else-
where [47]. The DNA fragment encoding PkRhopH2 was amplified from P. knowlesi A1-H.1
genomic DNA with primer pair PkRhopH2_F (ggtcgcggatccgaattcATGGAGTTAGGCCA
TACCGTG) and PkRhopH2_R (ggtggtggtgctcgagCTTCTCGATGTCTTCGTAGTCCA).
Lowercase letters indicate the plasmid-derived sequence and underlined letters indicate the
enzyme restriction sites for EcoRI and XhoI, respectively. A high fidelity KOD-plus kit was
Table 1. Characterization of P. vivax blood-stage antigen-specific antibodies, colocalization and the degree of similarity of homologous domains.
P. vivax Sal-I P. knowlesi strain H
Name PlasmoDB ID (Sal-
I)
MW (full length/ functional
domain)
Localization Ref. PlasmoDB ID % identity (aa.) of
functional domain with
two P. vivax strains
Colocalization Ref
Sal-I P01
PvMSP1P PVX_099975 214.6/9.6 Surface [33] PKNH_0728800 86.0 87.5 Surface [34]
PvMSP1 PVX_099980 196.1/9.8 Surface [35] PKNH_0728900 82.0 87.4 Surface [36]
PvMSP10 PVX_114145 52.3/47.0 Surface [37] PKNH_1129800 62.4 63.0 Surface [38]
PvMSP8 PVX_097625 54.7/49.3 Surface [39] PKNH_1031500 82.8 84.1 ND [38]
Pv41 PVX_000995 44.1/41.7 Surface [40] PKNH_0303000 83.7 83.7 Surface [41]
Pv50 PVX_087140 50.4/48.4 Surface [42] PKNH_0730000 58.2 57.8 Surface -
Pv32 PVX_084815 32.6/26.7 Surface [43] PKNH_0421000 77.3 76.8 Surface -
PvMSA180 PVX_094920 182.1/43.0 (N)
57.9 (C)
Surface
(N & C)
[44] PKNH_0814000 61.8 (N)
74.5 (C)
61.6 (N)
74.9 (C)
Surface
(N & C)
-
PvGAMA PVX_088910 82.7/57.5 Microneme [45] PKNH_1322900 82.4 82.5 Microneme -
PvDBP PVX_110810 119.7/38.5 Microneme [46] PKNH_0623500 71.4 70.7 ND [47]
PvAMA1 PVX_092275 64.5/64.5 Microneme [42] PKNH_0931500 85.4 85.0 Microneme [47]
PvRBP1a PVX_098585 326.3/34.4 Microneme [48] PkNBPXa
PKNH_1472300
PkNBPXb
PKNH_0700200
22.9 (Xa)
22.3 (Xb)
20.2
(Xa)
24.3
(Xb)
Microneme -
PvRBP1b PVX_098582 303.7/32.0 Microneme [48] PkNBPXa
PKNH_1472300
PkNBPXb
PKNH_0700200
26.9 (Xa) 31.3
(Xb)
16.7
(Xa)
14.6
(Xb)
Microneme -
Pv12 PVX_113775 41.1/36.0 Rhoptry neck [49] PKNH_1137300 74.9 75.2 Rhoptry NA
PvRON2 PVX_117880 244.6/68.9 Rhoptry neck [42] PKNH_1230100 71.0 78.0 ND� NA
PvRAMA PVX_087885 81.3/27.9 Rhoptry
body
[50] PKNH_0105800 74.6 75.6 ND�� NA
PvRhopH2 PVX_099930 160.9/42.6 Rhoptry
body
[51] PKNH_0727900 73.3 71.2 Rhoptry NA
PvETRAMP
11.2
PVX_003565 11.9/9.5 PVM [52] PKNH_0418600 74.7 80.2 ND NA
PvEXP1 PVX_091700 15.0/12.7 PVM [52] PKNH_0919300 77.5 79.6 ND NA
Identity of amino acid sequences was obtained based on the alignment of the target region shown in S1 Fig and colocalization on P. knowlesi parasites was determined
by the r2 value (>70%) in S1 Table.
MW, predicted molecular weight; FL, full length; NA, not assigned; ND: not defined; PVM, parasitophorous vacuole membrane; N, N-terminal; and C, C-terminal.
�, probably on the rhoptry neck
��, not in the rhoptry bulb.
https://doi.org/10.1371/journal.pntd.0008323.t001
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used with an initial denaturation step at 94˚C for 2 min, followed by 35 cycles of 94˚C for 15
sec, 60˚C for 30 sec, and 58˚C for 1.5 min and a final extension step at 68˚C for 10 min. The
amplicons were purified using a gel extraction kit and ligated into the pET28a(+) expression
vector with a His-tag. Correctly ligated plasmids were transformed into E. coli BL21(DE3).
The protein expression and purification was performed as described above. P. knowlesi MSP1-
19 protein was cloned into pGEX-4T-2 vector (GE Healthcare Life Sciences, Uppsala, Sweden)
by In-Fusion cloning according to manufacturer’s manual, and the cloned pDNAs were trans-
formed into BL21(DE3) competent cells for recombinant protein expression. The proteins
were purified with Glutathione Sepharose 4B (GE Healthcare Life Sciences) and used for mice
antibody production.
SDS-PAGE and western blot analysis
Parasite lysates were prepared from P. knowlesi schizont as described previously [55]. Recom-
binant proteins were separated by 13% SDS-PAGE under reducing or non-reducing condi-
tions and stained with 0.25% Coomassie brilliant blue R-250 (Sigma-Aldrich) and used for
western-blotting analysis [25]. The membrane-transferred proteins were reacted with primary
rabbit polyclonal serum (1:50) or an anti-His monoclonal antibody (1:2,000, Hilden, Ham-
burg, Germany) and then reacted with secondary IRDye-labeled goat anti-rabbit or goat anti-
mouse antibodies (1:10,000) (LI-COR Bioscience, Lincoln, NE). An Odyssey infrared imaging
system (LI-COR Bioscience) and Odyssey software (LI-COR Bioscience) were used to visualize
the bands.
Animal antibody production and IgG purification
All P. vivax blood-stage antigen-specific antibodies were obtained during our previous studies
(Table 1, S3 Table). Total IgG was purified from 1 mL of rabbit serum by using a protein G HP
column according to the manufacturer’s protocol (GE Healthcare Life Sciences) as described
elsewhere [47]. All animal experimental protocols were approved by the Institutional Ethics
Committee and followed the Ethical Guidelines for Animal Experiments of Kangwon National
University (KIACUC-16-0158).
Antigen-specific IgG antibody purification from patient serum samples
The serum samples used in this study were pooled from eight P. vivax-infected patients from
the ROK with a high response to the particular antigen of interest, which was screened by
immunoscreening with a protein microarray. The control comprised pooled serum samples
from eight healthy individuals from a nonendemic area of the ROK. Total IgG antibodies were
purified from the pooled serum samples by using protein G columns according to the manu-
facturer’s protocol (GE Healthcare Life Sciences). The isolated IgG antibodies were dialyzed
against RPMI 1640 medium and concentrated using centrifugal devices (Merck Millipore,
Darmstadt, Germany) with a 30-kDa cut-off value to a concentration of 10 to 20 mg/mL.
PvRBP1a, Pv41, and PvRhopH2 recombinant proteins (2–3 mg each) were immobilized on
cyanogen bromide (CNBr)-activated Sepharose 4 fast flow beads (GE Healthcare Life Sciences)
according to the manufacturer’s instructions. The total isolated IgG antibodies (0.5 mL) was
loaded to the column filled with antigen coupled beads and eluted using an elution buffer (0.1
M glycine, pH 2.7). The eluted antigen-specific IgGs were immediately neutralized with a Tris
buffer (pH 9.0) and dialyzed against incomplete RPMI 1640 medium to the desired
concentration.
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Immunofluorescence assay (IFA)
An IFA was performed as described previously [47]. The slides were dual probed with a panel
of rabbit polyclonal serum against P. vivax antigens (1:50) and mice serum against P. knowlesi
antigens as localization markers (PkMSP1-19 for merozoite surface, PkDBPα-II for microneme,
and PkRhopH2 for rhoptry; 1:50). Alexa Fluor 488 goat anti-mouse IgG (H+L) and Alexa Fluor
568 goat-anti rabbit IgG (H+L) were used as secondary antibodies. Nuclei were stained with
4’,6-diamidino-2-phenylindole (DAPI, Invitrogen). Red and green pixel intensities were ana-
lyzed by ImageJ. The scatter plots of individual red and green pixel intensities were then com-
pared and coefficient of determination (r-squared) was obtained. The larger r-squared (as close
to 100%) represents the scatter value around the regression line suggesting the variation of red
and green pixel intensities around its mean. Colocalization was determined as spatial overlap
between red (control) and green pixel intensities as showed in larger r-squared value.
Protein microarray
The protein microarray protocol was described elsewhere [25]. Serum was pooled from eight P.
vivax- and P. knowlesi-infected patients, healthy donors and/or individually used without pooling to
evaluate cross-immunoreactivity. The pooled or individual P. vivax- or P. knowlesi-infected patient
serum or healthy serum were diluted as 1:25. The cut-off value was equal to the mean fluorescence
intensity (MFI) plus two standard deviations (SDs) of the negative samples. Normalized MFI values
were calculated from the MFI/cut-off values. The normalized MFI for the pooled patient serum was
subtracted from the corresponding normalized MFI for the pooled healthy serum.
Growth inhibition assay
The standardized protocol for the invasion inhibition assay has been described elsewhere [47].
Briefly, 2 mg/mL purified rabbit IgG antibodies, and a concentration gradient of antigen-spe-
cific IgG antibodies from patients (0.1, 0.2, and 0.5 mg/mL) was added to a 96-well culture
plate containing P. knowlesi schizonts with 1.5% initial parasitemia and 2% hematocrit from
fresh human erythrocytes. An anti-Fy6 monoclonal antibody (25 μg/mL), which recognizes
the 2C3 epitope in the DARC N-terminal region located on the red blood cell surface mem-
brane, was obtained as previously described [56]. This antibody was a kind gift from Dr. Oliv-
ier Bertrand and Dr. Yves Colin (Institut National de la Transfusion Sanguine, Paris, France).
After 10 h of post-invasion for P. knowlesi, the parasites were stained with SYBR Green I
(Sigma-Aldrich) and analyzed with an Accuri C6 flow cytometer (Accuri cytometer Inc., Ann
Arbor, MI). Two independent experiments were performed in duplicate; three independent
experiments in duplicate were not possible due to limited antibody amount.
Data analysis
All calculations and data analysis were performed with GraphPad PRISM 5 (GraphPad Soft-
ware, Inc., San Diego, CA). The Mann-Whitney test was used to assess differences between
means, and one-way ANOVA with Dunnett’s test was used to compare the means from more
than two groups with control anti-HisGST; 95% confidence intervals (CIs), and p< 0.05 was
considered significant. The 50% inhibitory concentration (IC50) was plotted against log-trans-
formed antibody concentrations, and curve fitting by nonlinear regression with Excel software
was used to identify 50% parasite growth inhibition. Hierarchical clustering was used to calcu-
late the profile of individual seropositivity using TIGR multiarray experiment viewer (MeV)
software [57]. The clustering analysis was performed using average linkage clustering with
Euclidean distance as a similarity metric.
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Results
P. vivax blood-stage antigens are similar to those of P. knowlesi
Twenty rabbit antibodies previously generated against 19 P. vivax blood-stage vaccine candi-
dates were evaluated for their cross-species reactivity against P. knowlesi (S1 Fig). Of those,
most of the P. vivax antigens were highly expressed, and previous studies localized 8 to the
merozoite surface, 5 microneme molecules, 4 rhoptry molecules, and 2 dense granule mole-
cules (Table 1). The sequence alignment with orthologs of P. knowlesi (n = 18) revealed a high
degree of similarity, on average 75.2% for P. vivax Sal-I and 72.4% for P01 strain., in the
regions selected for antibody production (Table 1).
P. vivax blood-stage antigen-specific antibodies bind to P. knowlesi
antigens
Immunofluorescence assay (IFA) revealed that these antibodies recognized mature schizont-
or merozoite stage parasites of P. knowlesi (Figs 1–3), whereas antibodies from a PBS-immu-
nized rabbit (NI) and antibody raised against recombinant HisGST protein had no specific
reactivity to P. knowlesi parasites (Fig 3B). For the analysis of cross-reactivity to the surface
antigen of P. vivax merozoites, anti-PvMSP1-19, anti-PvMSP1P-19, anti-PvMSA180-N, anti-
PvMSA180-C, anti-Pv41, anti-PvMSP8, anti-PvMSP10, anti-Pv50, and anti-Pv32 antibodies
were used. Most of the surface antigens in P. knowlesi parasites were highly cross-reactive with
the 9 P. vivax antibodies and a positive control anti-PkMSP1-19 antibody (Fig 1). The anti-
PvMSP1-19 and PvMSA180-N antibody showed the strongest recognition of the surface of the
P. knowlesi merozoite, as shown by full overlap (r2 > 95%) with the anti-PkMSP1-19 signals
(Fig 1, S1 Table).
Fig 1. Cross-species reactivity of antibodies against P. vivax merozoite surface proteins to P. knowlesi parasites by
immunofluorescence assay. Localization of a panel of antibodies for P. vivax surface proteins (green) in P. knowlesi co-
stained with anti-PkMSP1-19 (red) as a surface marker. DIC, differential interference contrast; DAPI, 4’,6-diaminidino-
2-phenylindole (blue). All parasites shown are segmented schizonts (24–28 hours post-invasion). Bars indicate 5 μm.
https://doi.org/10.1371/journal.pntd.0008323.g001
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Most signals with antibodies against P. vivax microneme proteins, PvRBP1a, PvRBP1b,
PvGAMA, PvAMA1, and PvDBP, were colocalized with signals with anti-micronemal
PkDBPα antibody in P. knowlesi parasites (Fig 2A). Interestingly, antibodies against PvRBP1a
and PvRBP1b, for which the syntenic orthologs are pseudogenes in P. knowlesi, showed signals
for these parasites (Fig 2A).
Antibodies against P. vivax rhoptry body antigens (PvRhopH2) and rhoptry neck antigens
(PvRON2) cross-reacted with P. knowlesi showing complete (PvRhopH2) or partial (others)
colocalization signals for rhoptry body protein PkRhopH2 in P. knowlesi parasites, respectively
(Fig 2B, S1 Table). Antibodies against PvETRAMP11.2 and PvEXP1, which localize to the
parasitophorous vacuole/dense granules, partially overlapped with the MSP1-19 (surface) con-
sistent with a parasitophorous vacuole localization (Fig 3A). The western blot analysis using
parasite lysates showed that the P. vivax antibodies also recognized bands at expected full-
length sizes or probably the processing proteins (S2 Fig). PvMSP1-19 and PvRhopH2 antibod-
ies were surprisingly recognized the full length of MSP1 protein in P. knowlesi lysate. However,
non- specific recognition was seen in PvETRAMP11.2 which is in line that the PvE-
TRAMP11.2 antibody did not cross-react with P. knowlesi parasite organelle protein, but did
recognize the parasite membrane.
Antibodies raised against P. vivax blood-stage antigens inhibited the
erythrocyte invasion by P. knowlesi
We next investigated if antibodies raised against P. vivax antigens block human erythrocyte
invasion by P. knowlesi in vitro. We found that the invasion of P. knowlesi was inhibited by all
antibodies except RON2 when 2 mg/mL of P. vivax rabbit polyclonal IgG were administered
Fig 2. Cross-species reactivity of antibodies against P. vivax apical organelles proteins to P. knowlesi parasites by
immunofluorescence assay. (A) Localization of a panel of antibodies for P. vivax micronemal proteins (green) in P. knowlesi
co-stained with anti-PkDBPα (red) as a microneme marker and DAPI as nuclear marker (blue). (B) Localization of a panel
of antibodies for P. vivax rhoptry proteins (green) in P. knowlesi co-stained with anti-PkRhopH2 (red) as a rhoptry marker
and DAPI as nuclear marker (blue). All parasites shown are segmented schizonts (24–28 hours post-invasion). Bars indicate
5 μm.
https://doi.org/10.1371/journal.pntd.0008323.g002
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(Fig 4). The inhibition levels varied between the different antigens, but several were higher
than 60% (P41, MSP10, P50, RBP1a, RBP1b). Mild inhibition with dose-dependen manner
was observed with PvMSP1-19 and PvAMA1 antibodies (Fig 4, S3 Fig). The negative control
antibodies, anti-HisGST and PBS-immunized rabbit IgG (anti-NI) showed little to no inhibi-
tion, respectively. Administration of 2C3 monoclonal antibody, which targets Duffy antigens
on the erythrocyte, resulted in a high degree of inhibition (92.8 ± 1.6%) (Fig 4). Control anti-
bodies, anti-PkDBPα, and anti-PkAMA1 antibodies showed inhibition activity with dose-
dependent manner as described in our previous study [47] (S3 Fig).
To determine whether these antibodies demonstrate additive erythrocyte invasion inhibi-
tion, a combination of antibodies against three different antigens localized on the surface
(Pv41), microneme (PvRBP1a), and rhoptry (PvRhopH2) were combined in a total concentra-
tion of 2 mg/mL and evaluated. We found that a combination of these antibodies significantly
increased the invasion inhibition efficacy than single antibodies (S4 Fig).
Human antibodies against P. vivax blood-stage antigens inhibit erythrocyte
invasion by P. knowlesi
To confirm the cross-species inhibition activity of antibodies against P. vivax antigens, we
examined whether human antibodies against the P. vivax antigens in the serum of patients nat-
urally exposed to P. vivax infection could inhibit P. knowlesi erythrocyte invasion. Three P.
Fig 3. Cross-species reactivity of antibodies against P. vivax parasitophorous vacuole membrane molecules and
negative control antibodies to P. knowlesi parasites by immunofluorescence assay. (A) Localization of antibodies
for P. vivax parasitophorous vacuole proteins (green) in P. knowlesi co-stained with anti-PkMSP1-19 as a merozoite
surface marker. (B) Localization of PBS-immunized (NI) and HisGST antibodies to P. knowlesi. All parasites shown
are segmented schizonts (24–28 hours post-invasion). Bars indicate 5 μm.
https://doi.org/10.1371/journal.pntd.0008323.g003
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vivax antigens, PvRBP1a, Pv41, and PvRhopH2 (Fig 5A and 5B) were successfully produced
and used for immobilizing on CNBr beads to purify antigen-specific IgGs from the serum of
P. vivax-infected patients. These antigens were selected because each of them exhibited the
highest inhibitory activities within the same localization group (merozoite surface, microneme,
or rhoptry). The folded and unfolded PvRBP1a was then reacted with P. vivax-infected
patients serum, and showed reduction of positive reactivity to unfolded protein as compared
to folded PvRBP1a. It suggested that the protein was also successfully refolded (S5 Fig). The
patients living in vivax malaria endemic area in the Republic of Korea, would have had no pre-
vious exposure to P. knowlesi and were used to purify those three antigens specific human IgG.
Anti-Pv41- and anti-PvRhopH2-specific IgGs showed a concentration-dependent invasion
inhibition activity to P. knowlesi, whereas anti-PvRBP1a-specific IgG showed a very little inhi-
bition activity to P. knowlesi compared to naïve human IgG (Fig 5C).
Serum from knowlesi- or vivax-malaria patients recognized a panel of
vivax- and knowlesi recombinant proteins
To determine the cross-reactivity in malaria patients living in an endemic area, cross- immu-
noreactivity of antibodies from P. knowlesi- or P. vivax-infected patients was assessed using a
protein microarray of vivax and knowlesi-recombinant proteins. Serum from vivax- and
knowlesi-infected malaria patients recognized recombinant P. vivax and/or P. knowlesi pro-
teins at different levels of reactivity (Fig 6). PvMSP8 and PvMSA180-N recombinant antigens
are found to be more reactive to pooled P. knowlesi-infected serum (Fig 6A), while Pk50 was
very reactive to pooled P. vivax-infected serum (Fig 6B).
To further investigate the individual immunoprofiling for cross-reactivity, three P. knowlesi
recombinant proteins were used. Three most reactive antigens were selected from
Fig 4. Cross-species activity of antibodies against P. vivax antigens to inhibit erythrocyte invasion by P. knowlesi
parasites. Graph showing inhibition activity (%) of antibodies against P. vivax antigens to erythrocyte invasion by P.
knowlesi A1-H.1 (2 mg/mL rabbit IgG). PkDBPα, PkAMA1 rabbit polyclonal IgG, and 2C3 monoclonal antibody
served as control. NI, PBS-immunized rabbit IgG; DG, dense granules; 2C3, Anti-Fy6 monoclonal antibody (25 μg/
mL). Graphs show the mean and error bars denote ±1 SD of duplicate test wells in two independent experiments by
using one-way ANOVA with Dunnett’s multiple comparison test of means of antibody inhibition rate with mean of
control anti-HisGST. ns, no significant difference, p>0.05.
https://doi.org/10.1371/journal.pntd.0008323.g004
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immunoscreening results using pooled serum (Fig 6B, S6 Fig). The mean average of seroposi-
tive rate of these three antigens was higher to P. knowlesi-infected patient serum (61.9%) than
P. vivax-infected patient serum (43.3%) (Fig 7, Table 2). Of those, the PkMSA180-N is the
most reactive to P. knowlesi- and P. vivax-infected patient serum; 77.1 and 51.4%, respectively
(Table 2). In total, 37.1% (26/70) of P. knowlesi-infected patients showed seropositive to all
three P. knowlesi antigens and 27.1% (19/70) of P. vivax-infected patients showed seropositive
to all three P. knowlesi antigens (S7 Fig). This data indicates that these three proteins are highly
immunogenic and posses shared/common epitopes in the two species.
Discussion
Mixed infections are frequently discussed in the context of parasite-parasite interactions
among different Plasmodium spp. and a high degree of amino acid sequence similarity and
shared common epitopes for some parasites antigens suggests a potential role for cross-species
Fig 5. Growth inhibition activity of antigen-specific IgG from P. vivax-infected patients to P. knowlesi parasites.
(A) Different migration on SDS-PAGE of reduced and non-reduced recombinant proteins immobilized on agarose
beads. Proteins were successfully refolded as shown with Coomassie Brilliant Blue in different migration patterns with
and without DTT treatment. BSA was served as control. Proteins were then used for immobilization with CNBr-bead
for antigen-specific antibody purification from P. vivax-infected patients serum. (B) Western blot analysis of
recombinant PvRBP1a, PvRhopH2, and Pv41 proteins with anti-His-tag antibody. (C) Growth inhibition activity of
IgGs specific to P. vivax antigens to P. knowlesi. Different concentration of antigen-specific antibodies from human
(Pv41, PvRhopH2, PvRBP1a) ranging from 0.1, 0.2 and 0.5 mg/mL were used. IC50 of Pv41 antigen-specific human
antibodies was higher than PvRhopH2 antigen-specific human antibodies. αNaive indicates IgG purified healthy
individual who have never experienced malaria infection.
https://doi.org/10.1371/journal.pntd.0008323.g005
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immunity [21]. A proof-of-concept study in our laboratory reported that cross-species reactiv-
ity between P. vivax and P. knowlesi was observed for an apical asparagine-rich protein [25]. In
the current study, we characterized antibodies against 20 recombinant proteins derived from
19 P. vivax blood-stage vaccine candidates for their cross-reactivity to P. knowlesi. Genome
analysis of P. knowlesi revealed approximately 80% of genes that are orthologous to P. vivax, P.
falciparum. Among the 19 blood-stage antigens, we selected domains for expression based on
their importance for immune response or host cell receptor recognition that we have found in
our previous studies (Table 1). Whilst the majority of these had direct orthologues in P. know-
lesi, some did not, including PvRBP1a and PvRBPb which are found as pseudogenes in the P.
knowlesi.
We observed the antibodies against P. vivax antigens showed the expected localization pat-
tern for the surface or apical organelles of P. knowlesi based on the localization information on
P. vivax. Complete surface colocalization was observed with the anti-PvMSP1-19 antibody in
P. knowlesi, consistent with the 82.6% amino acid identities of PvMSP1-19 to orthologs of P.
knowlesi MSP1-19 and suggestive to a previous report [21]. Although syntenic orthologs of
PvRBP1a and PvRBP1b do not exist in P. knowlesi, these antibodies reacted to the apical side
of P. knowlesi merozoites, suggesting that non-syntenic paralogues were recognized, PkNBPXa
or PkNBPXb. Protein similarities may explain this phenomenon as similar protein sequences
do not always produce similar protein structures [58,59]. Previous studies supported that the
structural similarities observed among P. falciparum Erythrocyte membrane protein 1 vari-
ants, PvDBP and Variant surface antigen 2-CSA, and PvAMA1 and PfAMA1 were shown to
mediate cross-reactivity to a conserved epitope [60–62].
Fig 6. Cross-species reactivity of sera from P. knowlesi- and P. vivax-malaria clinical patients against P. vivax and/
or P. knowlesi proteins. (A) IgG responses of pooled P. vivax-infected patient serum from the Republic of Korea
(ROK) and knowlesi-infected patient serum (Malaysia) with P. vivax recombinant proteins after subtraction with
pooled healthy serum tier in 1:25 dilution. (B) IgG responses of pooled P. vivax-infected patient serum from the
Republic of Korea (ROK) and P. knowlesi-infected patient serum (Malaysia) with P. vivax recombinant proteins.
https://doi.org/10.1371/journal.pntd.0008323.g006
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The functional activity of P. vivax-specific antibodies against heterologous parasites was
also evaluated to determine whether antibodies could inhibit P. knowlesi invasion. We found
that compared with controls, most of the P. vivax-specific antibodies could effectively block
the invasion of P. knowlesi. Among all the antibodies, the anti-Pv41, anti-PvRBP1a, and anti-
Fig 7. P. knowlesi blood-stage cross-reactivity with individual patient serum. The human IgG response of PkMSP1-
42, PkMSA180-N, and PkAMA1. Individual with outlier reactivity was indicated in black dot. The prevalence of
antibody response was compared to the patients (K, knowlesi; V, vivax) and healthy (H) using the Mann-Whitney test.
��� = p<0.001.
https://doi.org/10.1371/journal.pntd.0008323.g007
Table 2. Seropositivity of IgG responses to top 3 antigens in P. knowlesi and P. vivax malaria patients and healthy individuals.
Antigens
(P. knowlesi)
Sample (n) No. of samples Sensitivity (%)a/ 95% CI (%)c MFId P valuee
Positive Negative Specificity (%)b
MSP1-42 P. knowlesi patient (70) 39 31 55.7a/ 44.1–66.8 1.59 P <0.0001
P. vivax patient (70) 29 41 41.4a/ 30.6–53.1 1.24 P = 0.0008
Healthy (30) 1 29 96.7b 83.3–99.4 0.59
AMA1 P. knowlesi patient (70) 37 33 52.9a/ 40.0−62.8 1.82 P <0.0001
P. vivax patient (70) 26 44 41.4a/ 26.8–48.9 1.49 P <0.0001
Healthy (30) 1 29 96.7b 83.3–99.4 0.68
MSA180-N P. knowlesi patient (70) 54 16 77.1a/ 66.1–85.4 1.49 P<0.0001
P. vivax patient (70) 36 34 51.4a/ 40.0–62.8 1.27 P = 0.0016
Healthy (30) 1 29 96.7b 83.3–99.4 0.58
a Sensitivity/ seropositivity rate: percentage of positive in malaria patient samples.
b Specificity/ seronegativity rate: percentage of negative in healthy samples.
c Confidence intervals.
d MFI, mean fluorescence intensity was divided by the cutoff value + 2 standard deviations above the MFI of healthy samples.
e P value, the difference in the total IgG level for each antigen between knowlesi or vivax malaria patients and healthy individuals were calculated with the Mann whitney
U-test. P value of <0.05 was considered statistically significant.
https://doi.org/10.1371/journal.pntd.0008323.t002
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PvRhopH2 antibodies appeared to have the highest growth inhibition assay, which is in line
with the recognition of either surface or apical organelles of the merozoite by these antibodies.
Interestingly, anti-PvAMA1 and anti-PvMSP1-19 antibodies, which also have strong recogni-
tion of native and recombinant proteins, did not show high inhibitory activity against human
erythrocyte invasion by P. knowlesi. This phenomenon was also observed in a previous study
[61] in which an anti-PvAMA1 antibody did not inhibit P. falciparum, even though immuno-
assays showed high cross-reactivity to merozoites, and highlights the need for functional char-
acterization of inhibitory activity. Despite the similarity in protein structure, the difference in
molecules charges in the MSP1-19 domain results in no functional antibody activity [36]. The
small change in the sequence may lead to a change in epitope recognition by changing the
affinity and avidity of the antibody due to the loss of the inhibitory effect of epitope-antibody
binding [63,64]. On the other hand, this study has limitation that we were not able to perform
the reverse-growth inhibition assay using P. knowlesi blood-stage antibodies against P. vivax
parasite, because of lack of long-term in vitro culture system of P. vivax parasites. Moreover,
the further studies are required to reinforce the cross-species reactivity study.
One of the critical issues of the current malaria vaccine development is the low efficacy, for
example, RTS,S vaccine showed only around 30% efficacy against children aged from 6–12
months after administration [65]. Such low protective efficacy would be improved if multiple
antigens are used. As compared to an antibody specific for the single antigen, pooled antibod-
ies for three antigens showed the additive effect to inhibit P. knowlesi invasion into human
erythrocytes. The selection of these antibodies may play a role in this observation, as it was
proposed that antibodies against merozoite surface slowed down the invasion to allow anti-
bodies against proteins secreted from microneme and rhoptry to bind their targets [66,67].
Southeast Asia is heavily endemic for P. vivax, and recently P. knowlesi is also recognized to
cause zoonotic human malaria in some regions in this area. Thus it is of interest to know if
antibodies against one species could play a role in the cross-protection against other Plasmo-
dium species. To this end, we found human IgG against P. vivax antigens is able to block the
erythrocyte invasion by P. knowlesi. Failure to inhibit P. knowlesi invasion with anti-PvRBP1a
IgG maybe because the epitopes recognized by this antibody were not protective epitopes of
PvRBP1a homologs in other Plasmodium species. However, the limitation of this study is that
we could not purify the knowlesi specific antibodies to perform the invasion inhibition assay
because we did not have enough P. knowlesi-infected patients’ serum at that time.
As part of the importance of cross-reactivity, the immunity produced against other species
could be one of the pivotal factors affecting the dynamic change in parasite-parasite interac-
tions. Previous studies have shown that serological cross-reactivity is observed between P. fal-
ciparum and P. vivax and between P. vivax and P. knowlesi [25,68]. In this study, three
different reactivities were observed for pooled P. knowlesi and/or P. vivax patients serum
against P. vivax and/or P. knowlesi antigens; (1) P. vivax patients sera are more reactive than P.
knowlesi patients sera to P. vivax antigens and vice versa, which is expected, (2) P. knowlesi
patients sera are more reactive than P. vivax patients sera to P. vivax antigens and vice versa,
which may be interpreted that cross-reacting epitopes exist not only in their closest orthologs
but also in other members encoded by a multigene family [60] so that the antibody binding
sites recognize the unrelated proteins [69], and (3) similar reactivity in both patients sera,
which suggests shared common epitopes with the closest orthologs. Surprisingly, this study
showed that approximately half of the human clinical patients from endemic area are cross-
reactive to P. knowlesi MSP1-42, MAS180-N or AMA1. These results are important evidence
indicating that immunity established against one Plasmodium species is able to cross-react
against other Plasmodium species through shared common epitopes. However, the regular
exposure to different Plasmodium species in one particular area may be correlated with the
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high reactivity of individual patient serum as it might lead to the accumulation of cross-
immune antibodies. It is also noted that some of the P. vivax-infected patients possess seropos-
itive to either single P. knowlesi antigen or in combination, highlighting the cross-protection
antibodies for which some patients in the endemic area develop less severe symptoms or low
parasitemia [70].
In the malaria pre-elimination era, the emergence of P. knowlesi and other zoonotic Plas-
modium species are one of the obstacles to successfully control malaria in Southeast Asian
countries. Cross-species invasion inhibition activities of antibodies against P. vivax shown in
this study provides important platform to design multi-component malaria vaccines and sug-
gesting the cross-species immunity affecting the disease dynamic change in Malaysia or
endemic area. Some patients in malaria-endemic area might possess different antibodies
against different Plasmodium species. However, the longevity of the cross-immune antibody is
still questioned, whether or not it can be maintained long enough to give a cross-protection
when the transmission change.
Supporting information
S1 Fig. Schematic diagrams of P. vivax blood-stage antigens with their homologs in P.
knowlesi. Regions used to raise antibodies are shown in brown boxes with the first and the last
amino acid positions at the top of diagram. The characteristic of each target was labeled into
different colors or patterns of the diagram with its amino acid position at the top. Four targets
(MSP1, MSP1P, MSP8, and MSP10) were identified the EGF-domain at the C-terminal region.
The characteristic of each target was obtained from www.plasmodb.org.
(TIF)
S2 Fig. Cross-species reactivity of P. vivax-specific antibodies with P. knowlesi parasites
assessed by western blot analysis. P. vivax-specific antibodies recognized P. knowlesi parasite
lysates. R, uninfected RBCs; P, P. knowlesi parasite lysate. The predicted full-length proteins
were shown in green, and the possible processing-protein products were indicated with red
arrowheads.
(TIF)
S3 Fig. The dose dependent growth inhibition activity of P. vivax and P. knowlesi antibod-
ies. Growth inhibition activity was evaluated using four different concentration (0.5; 1.0; 1.5
and 2.0/mL) rabbit IgG. The non immunized rabbit IgG and 2C3 monoclonal antibody were
served as controls. The dose dependent inhibition of activity of PkDBPα and PkAMA1 anti-
bodies were published online [47].
(TIF)
S4 Fig. Additive effect of combined antibodies against P. vivax proteins with different
localization to P. knowlesi. Growth inhibition activity was evaluated using 0.6 mg/mL rabbit
IgG as a single antibody or in combination of 3 antibodies at final 2 mg/mL. The single and
combination antibody was compared using one-way ANOVA with Dunnett’s test. ��� = p
value < 0.001.
(TIF)
S5 Fig. The human antibody response to PvRBP1a-F (folded) and PvRBP1a-UF (unfolded)
recombinant proteins. The prevalence of seropositivity was compared between patients (P: P.
vivax-infected patients) and healthy individual (H) using the Mann-Whitney test. � = p
value < 0.05; ns = non significant.
(TIF)
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S6 Fig. Western blot analysis of protein expression using the wheat germ cell-free analysis.
The expression level of each protein was detected by using anti-His tag antibody. Total fraction
(T) was then centrifuged to separate the soluble fraction (S) and pellet. A total 10 μL of proteins
were loaded in each well. His-tag antibody was used to confirm the positive band in western
blotting. The specific band that appears in the total fraction (T) was then said as non-soluble
protein. Otherwise soluble protein was showed in a specific band appear in both total fraction
and soluble fraction by western blotting.
(TIF)
S7 Fig. Heatmap of antibody response in each individual patient to the three different anti-
gens. (A) Antibody response to the three antigens in individual P. knowlesi-infected patients.
(B) Antibody response to the three antigens in individual P. vivax-infected patients. Hierarchi-
cal clustering of individual patients reactivity was showed by a vertical dendrogram. The clus-
ter of antibody reactivity in each patient for the three antigens was created based on the
Euclidean distance. The red asterisk indicates the same individual with all three seropositive
antigens. The color gradient (from blue to red) indicates the adjusted MFI value of antibody
reactivity.
(TIF)
S1 Table. The colocalization of P. vivax antibodies and P. knowlesi on IFA.
(DOCX)
S2 Table. Summary of cloning primers for P. knowlesi recombinant protein expression.
(DOCX)
S3 Table. Summary of P. vivax antibodies used in this study.
(DOCX)
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